Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety

Area of Science:

• Oncology
• Immunology
• Radiochemistry

Background:

• Epidermal growth factor receptor (EGFR) is a key target in cancer therapy due to its overexpression in various cancers.
• Therapeutic antibodies targeting EGFR are being explored for positron emission tomography (PET) imaging and image-guided surgery.
• Existing EGFR antibodies raise safety concerns like infusion reactions, limiting their diagnostic utility.

Purpose of the Study:

• To evaluate the safety and pharmacokinetic profile of IRDye800CW-nimotuzumab, a novel imaging agent for EGFR.
• To determine if nimotuzumab conjugated to IRDye800CW overcomes the safety limitations of other EGFR-targeting antibodies.

Main Methods:

• Formulation of IRDye800CW-nimotuzumab for clinical trial application.
• Comprehensive testing of physical, chemical, and pharmaceutical properties to establish product specifications and stability.
• Acute and delayed toxicity studies, along with non-compartmental pharmacokinetic analysis to determine half-life.

Main Results:

• IRDye800CW-nimotuzumab was confirmed to be non-toxic in both acute and delayed toxicity assessments.
• The determined half-life of IRDye800CW-nimotuzumab was approximately 38 ± 1.5 hours.
• Bi-exponential analysis yielded an alpha half-life of 1.5 hours and a beta half-life of 40.8 hours.

Conclusions:

• Preclinical studies demonstrate that nimotuzumab conjugated to IRDye800CW is safe for use as an imaging agent.
• This novel conjugate does not exhibit the toxicities commonly associated with EGFR-targeting antibodies.
• IRDye800CW-nimotuzumab presents a promising, safer alternative for EGFR-targeted imaging and surgical guidance.